![Klaus Fiebig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Klaus Fiebig is Chief Scientific Officer & VP-Research Programs at Ontario Genomics Institute (Private Equity).
Dr. Fiebig joined OGI in February 2006.
Most recently, Dr. Fiebig was Senior Director of Structural Biology and Computational Chemistry at Affinium Pharmaceuticals in Toronto, where he directed a 20-person strategic alliance with Pfizer that focused on structural proteomics and structure-based drug discovery.
Previously, Dr. Fiebig co-founded and was CEO of MRPharm (Frankfurt), which focused on NMR-based drug discovery.
His academic team at the University of Frankfurt worked on drug discovery with Aventis.
Dr. Fiebig was also a lead scientist with Xencor (Los Angeles), improving its automatic computational platform for designing proteins.
Dr. Fiebig received his PhD in Pharmaceutical Chemistry from the University of California at San Francisco and his undergraduate degree in Physics from the Technical University Munich.
With fellowships from the Burroughs Wellcome Fund and the Howard Hughes Medical Institute, he completed postdoctoral research in protein folding at the University of Oxford and work in structural biology at Yale University.
| Sociétés | Poste | Fin |
|---|---|---|
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Provides clinical development of antibacterial | Corporate Officer/Principal | - |
| XENCOR, INC. | Corporate Officer/Principal | - |
Ontario Genomics Institute (Private Equity)
 Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute invests in companies located in Canada. The firm targets companies operating in the fields of Human health, Agriculture & Food, Bioproducts & environment. | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Technische Universität München
 Technische Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Provides clinical development of antibacterial | Health Technology |
Ontario Genomics Institute (Private Equity)
Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute invests in companies located in Canada. The firm targets companies operating in the fields of Human health, Agriculture & Food, Bioproducts & environment. | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
